Skip to main content
SpringerLink
Log in

PDE inhibitors: early promise in asthma not yet converted to clinical success

  • New drugs and diseases management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 2000; 59 (2): 193–212

    Article  PubMed  CAS  Google Scholar 

  2. Fujishige K, Kotera J, Michibata H, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyses both cAMP and cGMP (PDElOA). J Biol Chem 1999; 274: 18438–45

    Article  PubMed  CAS  Google Scholar 

  3. Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 1997; 22: 217–24

    Article  PubMed  CAS  Google Scholar 

  4. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351–70

    Article  PubMed  CAS  Google Scholar 

  5. Jonker GJ, Tijhuis GJ, De Monchy JGR. RP 73401 (a phosphodiesterase IV inhibitor) single dose does not prevent allergen-induced bronchoconstriction during the early phase reaction in asthma [abstract]. Eur Respir J 1996; 9: 82S

    Google Scholar 

  6. Harbinson PL, MacLeod D, Hawksworth R, et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10: 1008–14

    Article  PubMed  CAS  Google Scholar 

  7. McGrath JL, Aikman SL, Cook RM, et al. Six weeks treatment with inhaled RP 73401, a PDE IV inhibitor: effect on airway hyperresponsiveness and exhaled nitric oxide in mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1997; 155: A660

    Google Scholar 

  8. Norman P. PDE4 inhibitors 1998. Exp Opin Ther Pat 1998; 8: 771–84

    Article  CAS  Google Scholar 

  9. Compton CH, Cedar E, Nieman RB, et al. Ariflo™ improves pulmonary function in patients with asthma: results of a study in patients taking inhaled corticosteroids [abstract]. Am J Respir Crit Care Med 1999; 159: A522

    Google Scholar 

  10. Nieman RB, Fisher BD, Amit O, et al. SB 207499 (Ariflo™), a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise-induced bronchoconstriction in patients with asthma [abstract]. Am J Respir Crit Care Med 1998; 157: A413

    Google Scholar 

  11. Leeman M, Lejeune P, Melot C, et al. Reduction in pulmonary hypertension and in airway resistance by enoximone (MDL 17,403) in decompensated COPD. Chest 1987; 91: 662–6

    Article  PubMed  CAS  Google Scholar 

  12. Bardin PG, Dorward MA, Lampe FC, et al. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 1998; 45 387–91

    Article  PubMed  CAS  Google Scholar 

  13. Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 1999; 160; 817–20

    Article  PubMed  CAS  Google Scholar 

  14. Markham A, Faulds D. Theophylline: a review of its potential steroid sparing effects in asthma. Drugs 1998; 56: 1081–91

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

PDE inhibitors: early promise in asthma not yet converted to clinical success. Drugs Ther. Perspect 16, 8–10 (2000). https://doi.org/10.2165/00042310-200016110-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200016110-00003

Keywords

Search

Navigation